display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
billiary tract cancer - 1st line (L1)
billiary tract cancer - 1st line (L1)
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab plus SoC TOPAZ-1
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-966
Immune checkpoint association
nivolumab plus ipilimumab HUM00126271

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons